Cargando…
Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment
In head and neck cancer management, there is a need for tailored approaches to optimally implement clinical outcomes. Based on the assumption that efficacy and long-term toxicity are not satisfactory for standard concurrent platinum-based chemoradiotherapy, several trials have been designed to test...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151395/ https://www.ncbi.nlm.nih.gov/pubmed/34068797 http://dx.doi.org/10.3390/jpm11050393 |
_version_ | 1783698372770660352 |
---|---|
author | De Felice, Francesca Musio, Daniela Tombolini, Vincenzo |
author_facet | De Felice, Francesca Musio, Daniela Tombolini, Vincenzo |
author_sort | De Felice, Francesca |
collection | PubMed |
description | In head and neck cancer management, there is a need for tailored approaches to optimally implement clinical outcomes. Based on the assumption that efficacy and long-term toxicity are not satisfactory for standard concurrent platinum-based chemoradiotherapy, several trials have been designed to test whether induction immunotherapy and/or concomitant immunotherapy and radiotherapy result in improved survival and toxicity outcomes. Here, we present an overview of the most recent concomitant therapeutic strategies for head and neck cancer, focusing on the knowledge available regarding check-point inhibitors. The aim is to present the characteristics of the main check-point inhibitors and to summarize the clinical trials on the combination of immune check-point inhibitors and (chemo)radiotherapy in the definitive HNC setting, in order to provide a useful clinical tool for further research. |
format | Online Article Text |
id | pubmed-8151395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81513952021-05-27 Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment De Felice, Francesca Musio, Daniela Tombolini, Vincenzo J Pers Med Review In head and neck cancer management, there is a need for tailored approaches to optimally implement clinical outcomes. Based on the assumption that efficacy and long-term toxicity are not satisfactory for standard concurrent platinum-based chemoradiotherapy, several trials have been designed to test whether induction immunotherapy and/or concomitant immunotherapy and radiotherapy result in improved survival and toxicity outcomes. Here, we present an overview of the most recent concomitant therapeutic strategies for head and neck cancer, focusing on the knowledge available regarding check-point inhibitors. The aim is to present the characteristics of the main check-point inhibitors and to summarize the clinical trials on the combination of immune check-point inhibitors and (chemo)radiotherapy in the definitive HNC setting, in order to provide a useful clinical tool for further research. MDPI 2021-05-10 /pmc/articles/PMC8151395/ /pubmed/34068797 http://dx.doi.org/10.3390/jpm11050393 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review De Felice, Francesca Musio, Daniela Tombolini, Vincenzo Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment |
title | Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment |
title_full | Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment |
title_fullStr | Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment |
title_full_unstemmed | Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment |
title_short | Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment |
title_sort | immune check-point inhibitors and standard chemoradiotherapy in definitive head and neck cancer treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151395/ https://www.ncbi.nlm.nih.gov/pubmed/34068797 http://dx.doi.org/10.3390/jpm11050393 |
work_keys_str_mv | AT defelicefrancesca immunecheckpointinhibitorsandstandardchemoradiotherapyindefinitiveheadandneckcancertreatment AT musiodaniela immunecheckpointinhibitorsandstandardchemoradiotherapyindefinitiveheadandneckcancertreatment AT tombolinivincenzo immunecheckpointinhibitorsandstandardchemoradiotherapyindefinitiveheadandneckcancertreatment |